论文部分内容阅读
目的观察唑来磷酸对绝经后乳腺癌患者应用阿那曲唑内分泌治疗导致骨量减少的影响。方法绝经后雌激素受体阳性乳腺癌患者53例,在应用钙剂联合维生素D3制剂基础上分别采用唑来磷酸联合阿那曲唑(治疗组,23例)和阿那曲唑(对照组,30例)治疗。用药方法:唑来磷酸4mg/28d静脉滴注,阿那曲唑1mg/d口服。观察治疗前和治疗6、12、18个月骨密度(BMD)变化。结果与治疗前比较,治疗期治疗组BMD明显升高(P<0.05),而对照组BMD无明显变化(P>0.05)。结论加用唑来磷酸治疗能明显防止绝经后乳腺癌患者阿那曲唑引起的骨量减少作用。
Objective To observe the effect of zoledronic acid on the incidence of osteopenia after anastrozole endocrine therapy in postmenopausal women with breast cancer. Methods 53 cases of postmenopausal estrogen receptor positive breast cancer patients were treated with zalophosphate plus anastrozole (treatment group, 23 cases) and anastrozole (control group, 30 cases )treatment. Medication: Zoledronic acid 4mg / 28d intravenous infusion, anastrozole 1mg / d orally. Bone mineral density (BMD) changes before and 6, 12, and 18 months after treatment were observed. Results Compared with those before treatment, BMD in the treatment group was significantly increased (P <0.05), while there was no significant change in the control group (P> 0.05). Conclusion Addition of zoledronic acid treatment can significantly prevent the effect of anastrozole-induced osteopenia in postmenopausal women with breast cancer.